• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanobiotix seeks to boost cancer care with nanoparticle-radiotherapy combo

June 23, 2017 By Sarah Faulkner

Nanobiotix nanoparticleIncreasingly, pharma and biotech companies are looking towards personalized medicine to guide their portfolios, developing therapies designed to address the needs of individual patient populations.

Nanobiotix (EMA:NANO) has chosen to look in the other direction, according to co-founder & CEO Laurent Levy.

“What we have done in our company is trying to go for the opposite: to find 1 product that could potentially help millions of patients,” Levy told Drug Delivery Business News.

The Paris-based company is testing its NanoXray technology in an array of cancer types – from soft tissue sarcoma to liver cancer. The company has 7 on-going clinical trials across Europe, the U.S. and 2 countries in Asia, Levy said.

This month, Nanobiotix touted data from its Phase I/II head and neck cancer trial at the American Society of Clinical Oncology meeting.

Levy

The study enrolled patients ages 70 or older with advanced stage III/IV  cancer. After treatment with Nanobiotix’s nanoparticle product, NBTXR3, 7 out of 9 patients had a complete response at the 10% dose level. Also, the candidate demonstrated a strong safety profile, with no adverse treatment-related events.

After 12 months of follow-up, none of the patients treated at the high dose of NBTXR3 have relapsed, Levy said.

The company’s platform technology was designed to boost the effects of radiotherapy within cancerous tissue without increasing the dose of radiation that healthy tissue is exposed to during treatment.

The nanoparticle treatment can be either locally injected or administered systemically, at which point it accumulates in the cancerous tissue. When it’s exposed to ionizing radiation, the nanoparticles generate massive amounts of electrons, amplifying the dose of energy within the tumor.

“The product is meant to increase the dose within the tumor without increasing the dose in surrounding tissue,” Levy said.

From day 1 of the treatment until the end of radiotherapy, the amplified energy stays within the tumor.

Also at ASCO, the company highlighted data from a 26-patient Phase II/III trial in soft tissue sarcoma. The data showed that radiotherapy-nanoparticle combo can switch “cold” tumors to “hot” tumors, rendering them vulnerable to a patient’s immune system.

Levy said the company hopes to win its 1st European approval in soft tissue sarcoma by the end of 2017.

“We may have 1 of those rare products in oncology where you could have something that will impact survival, quality of life and good, if not excellent, safety.”

Filed Under: Clinical Trials, Featured, Nanoparticles, Oncology, Research & Development, Wall Street Beat Tagged With: nanobiotix

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS